Clinical trials: Polymyalgia Rheumatica
Giant Cell Arteritis, Neurovascular Disorder
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
A French multicenter randomised and placebo-controlled study recruiting patients who present neurovascular involvement related to GCA (> 60 years) with symptomatic (stroke) or asymptomatic forms.
- Trial name
- TOGIAC (NCT04888221)
- Testing
- Tocilizumab
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Polymyalgia Rheumatica
Validation of the PMR Activity Score and Evolution of Patient-reported Outcomes in Patients With Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease that affects elderly people. It is characterized by pain and morning stiffness in the shoulders, pelvic girdles and neck.
- Trial name
- NCT05542316
- Where
- Belgium
- Volunteers
- 133 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Polymyalgia Rheumatica
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder with unknown etiology and overlapping symptoms with giant cell arthritis and rheumatoid arthritis (RA).
- Trial name
- NCT05681676
- Testing
- Blood samples before and after standard of care of polymyalgia rheumatica
- Volunteers
- 9 people
- Sponsor
- Aalborg University
Polymyalgia Rheumatica
Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica
Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.
- Trial name
- TENOR-IMMUNO (NCT02888496)
- Testing
- tocilizumab
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Rheumatoid Arthritis, Idiopathic Juvenile Arthritis
Pharmacogenetic Studies on Anti-IL-6 Receptor Monoclonal Antibodies on the Treatment of Rheumatic Diseases
Tocilizumab and Sarilumab are first-line biological disease-modifying anti-rheumatic drug (bDMARD) which inhibits Interleukin 6 (IL-6) pathway through blockade of its receptor on the treatment of Rheumatoid Arthritis and other…
- Conditions
- Rheumatoid Arthritis, Idiopathic Juvenile Arthritis, Giant Cell Arteritis, Still Disease
- Trial name
- NCT05045001
- Where
- Spain
- Volunteers
- 140 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Polymyalgia Rheumatica, Giant Cell Arteritis
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Background: Polymyalgia rheumatica (PMR) is characterised by pain of the proximal muscles, general symptoms, and raised inflammatory markers. Treatment with prednisolone has several adverse effects.
- Conditions
- Polymyalgia Rheumatica, Giant Cell Arteritis, Adrenal Insufficiency
- Trial name
- NCT04519580
- Testing
- PET/CT
- Where
- 3 sites in Denmark
- Volunteers
- 98 people
- Sponsor
- Kresten Krarup Keller
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Giant Cell Arteritis (GCA)
Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA)
B cells are a component of the immune system which appear be important in causing all forms of cardiovascular disease. Until now, it has not been possible to directly study these cells in living patients (essential to assess…
- Trial name
- RituxiMAP GCA (NCT07269938)
- Testing
- Zirconium Zr 89 labelled rituximab
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Polymyalgia Rheumatica
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
The study compares the efficacy and safety of modified release prednisone versus immediate release prednisone in patients suffering from polymyalgia rheumatica.
- Trial name
- NCT01821040
- Testing
- Lodotra®, Prednisone IR (immediate release)
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Mundipharma Research Limited
Giant Cell Arteritis, Polymyalgia Rheumatic (PMR)
Giant Cell Arteritis - Ways to Precision Medicine
Long-term follow-up of aortal adverse events, as well as glucocortioid-associated adverse events in patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).
- Trial name
- NCT07084480
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Wuerzburg University Hospital
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Inflammatory Rheumatism, Polymyalgia Rheumatica
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy.
- Conditions
- Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies
- Trial name
- PRODIGIOUS (NCT04664465)
- Where
- 12 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis, Polymyalgia Rheumatica
Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR).
- Trial name
- GCAIO (NCT06460142)
- Testing
- Aortic/ cardiac magnetic resonance imaging, Vascular ultrasound, Transorbital Ultrasound
- Where
- Germany
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to…
- Trial name
- NCT04474847
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Polymyalgia Rheumatica, Rheumatoid Arthritis
Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica
The aim of this study is to evaluate a simple and rapid method in order to better define and treat Polymyalgia Rheumatica by measuring levels of muscle achiness and pain with a blood pressure cuff.
- Conditions
- Polymyalgia Rheumatica, Rheumatoid Arthritis, Rheumatic Disease
- Trial name
- NCT00847236
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Lahey Clinic
Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)
Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis
This prospective study is to explore different predictive factors for response to steroid treatment in patients with PMR and/or GCA.
- Trial name
- NCT05479448
- Testing
- Data collection for cellular analyses (Immune subset composition, GCR expression, in vitro steroid responsiveness), Data collection for exploratory analyses of endogenous steroid hormones, Data collection for correlation between clinical defined and lab defined GC responsivness
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Giant Cell Arteritis
A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
The goal of this open-label clinical trial is to evaluate the efficacy of AzaFol-PET/CT in the diagnosis of GCA (giant cell arteritis), to compare AzaFol- with 2-[18F]FDG-PET/CT, and to assess the safety and tolerability of…
- Trial name
- CRAFT (NCT06335888)
- Testing
- AzaFol, FDG
- Where
- Switzerland
- Volunteers
- 70 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Temporal Arteritis
Determining Disease Activity Biomarkers in Individuals With Giant Cell Arteritis
Giant cell arteritis (GCA), also known as temporal arteritis, is a disease that usually only occurs in older adults. GCA causes inflammation of blood vessels, or vasculitis.
- Trial name
- NCT00315497
- Where
- 9 sites in United States, Canada
- Volunteers
- 426 people
- Sponsor
- University of Pennsylvania
Polymyalgia Rheumatica
Delayed Release Prednisone in PMR
A four-week, randomized, controlled, open-label trial of DR prednisone in which patients receive in period 1 one of three-night time doses of treatment (4mg, 7mg or 10mg) for two weeks followed in period 2 by treatment with 15mg…
- Trial name
- NCT02702778
- Testing
- Delayed-Release (DR) Prednisone, Immediate Release (IR) Prednisone
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Dinora, Inc.